초록 ▼

The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover

The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin diseases such as atopic dermatitis. An external preparation for skin which contains one or more compounds selected from the group consisting of 5-aminolevulinic acid, its salt and a derivative of them; and an iron compound; as active components, is used.

대표청구항 ▼

1. A method for inhibiting progression of or ameliorating skin roughness, dry skin, wrinkles, sagging skin and flecks and/or atopic dermatitis, said method comprising: administering transdermally an external preparation for skin, wherein the external preparation for skin contains (A) an iron compoun

1. A method for inhibiting progression of or ameliorating skin roughness, dry skin, wrinkles, sagging skin and flecks and/or atopic dermatitis, said method comprising: administering transdermally an external preparation for skin, wherein the external preparation for skin contains (A) an iron compound selected from the group consisting of ferrous citrate, iron sodium citrate, iron ammonium citrate, iron acetate, iron oxalate, ferrous succinate, iron and sodium succinate citrate, ferrous pyrophosphate, ferric pyrophosphate, heme iron, iron dextran, iron lactate, ferrous gluconate, iron sodium diethylenetriaminepentaacetate, iron ammonium diethylenetriaminepentaacetate, iron sodium ethylenediaminetetraacetate, iron ammonium ethylenediaminetetraacetate, iron triethylenetetraamine, iron sodium dicarboxymethylglutamate, and iron ammonium dicarboxymethylglutamate in an amount of 0.5 to 50 wt % based on the total weight of the external preparation for skin, and(B) 5-aminolevulinic acid, a pharmaceutically acceptable salt of 5-aminolevulinic acid or a pharmaceutically acceptable ester derivative of 5-aminolevulinic acid or the salt thereof in an amount of 0.1 to 10 wt % based on the total weight of the external preparation, wherein each component of the preparation is administered transdermally either simultaneously or immediately sequentially in a same location of the skin. 2. The method according to claim 1, wherein the external preparation for skin further contains urea. 3. The method according to claim 2, wherein the iron compound is ferrous citrate, iron sodium diethylenetriaminepentaacetate, or iron ammonium diethylenetriaminepentaacetate. 4. The method according to claim 1, wherein the iron compound is ferrous citrate, iron sodium diethylenetriaminepentaacetate, or iron ammonium diethylenetriaminepentaacetate. 5. A method according to claim 1 wherein administering transdermally the external preparation for skin comprises administering transdermally the component (A), and then administering transdermally the component (B) immediately sequentially in a same location;administering transdermally the component (B), and then administering transdermally the component (A) immediately sequentially in a same location; oradministering transdermally the component (A) and the component (B) simultaneously in a same location. 6. The method according to claim 5, wherein the component (A) and/or the component (B) further contain urea. 7. A method for inhibiting progression of or ameliorating skin roughness, dry skin, wrinkles, sagging skin and flecks and/or atopic dermatitis, said method comprising administering transdermally an external preparation for skin, wherein the external preparation for skin is consists essentially of: (A) an iron compound selected from the group consisting of ferrous citrate, iron sodium citrate, iron ammonium citrate, iron acetate, iron oxalate, ferrous succinate, iron and sodium succinate citrate, ferrous pyrophosphate, ferric pyrophosphate, heme iron, iron dextran, iron lactate, ferrous gluconate, iron sodium diethylenetriaminepentaacetate, iron ammonium diethylenetriaminepentaacetate, iron sodium ethylenediaminetetraacetate, iron ammonium ethylenediaminetetraacetate, iron triethylenetetraamine, iron sodium dicarboxymethylglutamate, and iron ammonium dicarboxymethylglutamate in an amount of 0.5 to 50 wt % based on the total weight of the external preparation for skin; and(B) 5-aminolevulinic acid, a pharmaceutically acceptable salt of 5-aminolevulinic acid or a pharmaceutically acceptable ester derivative of 5-aminolevulinic acid or the salt thereof in an amount of 0.1 to 10 wt % based on the total weight of the external preparation,wherein each component of the preparation is administered transdermally either simultaneously or immediately sequentially in a same location of the skin. 8. A method for inhibiting progression of or ameliorating skin roughness, dry skin, wrinkles, sagging skin and flecks and/or atopic dermatitis, said method comprising administering transdermally an external preparation for skin, wherein the external preparation for skin is consists essentially of (a) an iron compound selected from the group consisting of ferrous citrate, iron sodium citrate, iron ammonium citrate, iron acetate, iron oxalate, ferrous succinate, iron and sodium succinate citrate, ferrous pyrophosphate, ferric pyrophosphate, heme iron, iron dextran, iron lactate, ferrous gluconate, iron sodium diethylenetriaminepentaacetate, iron ammonium diethylenetriaminepentaacetate, iron sodium ethylenediaminetetraacetate, iron ammonium ethylenediaminetetraacetate, iron triethylenetetraamine, iron sodium dicarboxymethylglutamate, and iron ammonium dicarboxymethylglutamate in an amount of 0.5 to 50 wt % based on the total weight of the external preparation for skin,(b) 5-aminolevulinic acid, a pharmaceutically acceptable salt of 5-aminolevulinic acid or a pharmaceutically acceptable ester derivative of 5-aminolevulinic acid or the salt thereof is in an amount of 0.1 to 10 wt % based on the total weight of the external preparation, and(c) urea in an amount of 0.1 to 10 w/w % of the total weight of the external preparation,wherein each component of the preparation is administered transdermally either simultaneously or immediately sequentially in a same location of the skin. 9. A method for inhibiting progression of or ameliorating skin roughness, dry skin, wrinkles, sagging skin and flecks and/or atopic dermatitis, said method comprising administering transdermally an external preparation for skin, wherein the external preparation for skin is consists essentially of (a) an iron compound selected from the group consisting of ferrous citrate, iron sodium diethylenetriaminepentaacetate, and iron ammonium diethylenetriaminepentaacetate in an amount of 0.5 to 50 wt % based on the total weight of the external preparation for skin,(b) 5-aminolevulinic acid, a pharmaceutically acceptable salt of 5-aminolevulinic acid or a pharmaceutically acceptable ester derivative of 5-aminolevulinic acid or the salt thereof is in an amount of 0.1 to 10 wt % based on the total weight of the external preparation, and(c) urea in an amount of 0.1 to 10 w/w % of the total weight of the external preparation,wherein each component of the preparation is administered transdermally either simultaneously or immediately sequentially in a same location of the skin.